These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29278014)

  • 41. Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.
    Chen Y; Lairson DR; Chan W; Huo J; Du XL
    J Manag Care Spec Pharm; 2017 Aug; 23(8):831-843. PubMed ID: 28737990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
    Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M
    Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain.
    Vo P; Gao W; Zichlin ML; Fuqua E; Fadli E; Aguirre Vazquez M; Tarancón T; Mahieu N; Maier-Peuschel M; Rossi S; Naclerio M; Ritrovato D; Swallow E
    J Med Econ; 2019 Sep; 22(9):953-959. PubMed ID: 31234672
    [No Abstract]   [Full Text] [Related]  

  • 48. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
    Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G;
    Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating retinal vein occlusions in France, Germany, and Italy: an analysis of treatment patterns, resource consumption, and costs.
    Augustin AJ; Sahel JA; Cerulli L; Texier-Richard B; Buchholz PM; Kobelt G
    Eur J Ophthalmol; 2012; 22(5):776-84. PubMed ID: 22729442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.
    Ailawadhi S; Medhekar R; Princic N; Fowler R; Tran O; Bhowmik D; Panjabi S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1070-1079. PubMed ID: 31631810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain.
    Vo P; Swallow E; Wu E; Zichlin ML; Katcher N; Maier-Peuschel M; Naclerio M; Ritrovato D; Tiwari S; Joshi P; Ferraris M
    J Med Econ; 2021; 24(1):900-907. PubMed ID: 34311659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.
    Jönsson L; Justo N; Musayev A; Krishna A; Burke T; Pellissier J; Judson I; Staddon A; Blay JY
    Eur J Cancer Care (Engl); 2016 May; 25(3):466-77. PubMed ID: 25923192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
    Kim MY; Sposto R; Swaika A; Asano H; Alamgir A; Chanan-Khan A; Ailawadhi S
    Oncology; 2014; 87(4):224-31. PubMed ID: 25059308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M; Sharma A; Chung KC; Delea TE
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.
    Brøndum RF; Vestergaard AS; Børty L; Vesteghem C; Rytter AS; Nielsen MM; Severinsen MT; Jensen P; Gregersen H; El-Galaly TC; Dybkær K; Ehlers LH; Bøgsted M; Roug AS
    Future Oncol; 2021 Sep; 17(25):3331-3341. PubMed ID: 34156281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost of skeletal complications from bone metastases in six European countries.
    Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
    J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.